Walter and Eliza Hall Institute researchers have launched one of the largest international efforts to prevent and treat maternal anaemia in developing countries.
The study will also investigate the impacts of iron deficiency on the developing infant brain.
The trials, which have just opened in Malawi and Bangladesh, are aiming to recruit more than 6,000 women and children.
The research is being led by Institute haematologist Dr Sant-Rayn Pasricha, along with collaborators at the University of Melbourne in Australia, University of Malawi in Africa, and the International Centre for Diarrhoeal Diseases Research in Bangladesh.
Anaemia is one of the most avoidable causes of illness and death in the developing world with serious health implications for hundreds of millions of mothers and babies.
Dr Pasricha said The World Health Organization (WHO) had set an ambitious target of halving the prevalence of anaemia in women by 2025.
“There has been almost no progress towards achieving the WHO target. Our efforts are aiming to change that. Through these pivotal trials, we want to find efficient and effective treatment strategies to help women and children reach their full iron needs,” said Dr Pasricha.
“We hope our findings will provide governments and the WHO with vital knowledge to improve public health policy and tackle this major challenge to global health.”
The current oral treatment approaches in lower-income communities in Africa and Asia are having a particularly devastating impact on global maternal health.
Dr Pasricha said current iron pill programs in poorer areas were ineffective because they required multiple healthcare centre visits over an extended period of time.
“The level of diligence required to keep up a full course of iron pills, limited access to medical centres and poor health infrastructure means an overwhelming number of pregnant women aren’t getting the iron they need,” he said.
A Malawi-based trial is now underway with the support of $4 million in grants from The Bill & Melinda Gates Foundation. The trial will test the impact of an intravenous iron treatment used successfully in developed countries such as Australia that can safely and rapidly boost iron count to recommended levels in one 15 minute session.
“In addition to the life-saving benefits for mothers, previous studies have shown that successful iron interventions increased gestation periods by half a week, almost halved the incidence of prematurity, and improved birth weights by 150 grams,” said Dr Pasricha.
A further two trials in Malawi and Bangladesh, backed by more than $7.5 million in funding from the NHMRC, will gather world-first evidence on the risks and benefits of mass iron intervention for babies in developing countries.
Dr Pasricha said the positive impacts of iron on brain development and physical growth had been widely assumed for decades. Yet there was no existing data to support the theory.
“With the help of trained psychologists, we will gather evidence on the impact of iron on cognitive development, behaviour and physical growth measures such as height and weight.
“In addition to brain development, the studies will assess the associated risks of iron intervention in children in poorer communities, such as increased susceptibility to diseases that thrive on iron in the blood, including malaria and some bacterial infections such as salmonella and E. coli,” said Dr Pasricha.
Dr Pasricha continued, “We hope to provide a rationale for the prudent allocation of government funds and resources, as well as improvements for administering iron through public health programs worldwide.”